Book of Abstracts - New Frontiers 2022

Program overview

14:00 – 15:40

SESSION 2. SUCCESS AND FAILURE OF CARDIAC THERAPY: WHAT FACTORS MATTER?

Chairs: A. Meli (Montpellier, France), M. Štěrba (Hradec Kr á lov é , Czech Republic)

14:00 – 14:20

N. S. Dhalla (Winnipeg, Canada) Rationale for the prevention or therapy of sudden cardiac death in heart failure

14:20 – 14:40

M. Souidi, J. Resta, Y. Sleiman, S. Reiken, P. Amedro, P. Meyer, A. Charrabi, O. Cazorla, M. Vincenti, S. Blot, F. Rivier, A. Parini, A. Marks, J. Mialet-Perez, A. Lacampagne, A. Meli (Montpellier, France) Patient-specific derived cardiomyocytes: will we be able to predict the cardiomyopathies in the dish tomorrow?

14:40 – 15:00

M. Štěrba (Hradec Kr á lov é , Czech Republic) Pharmacological cardioprotection against chronic ANT cardiotoxicity – topoisomerase II beta targeting and beyond

15:00 – 15:20

A. Görbe , Z. Giricz, P. Ferdinandy (Budapest, Szeged; Hungary) Hidden cardiotoxicity - cardiac safety testing in ischemic and comorbid conditions: development of preclinical test platforms

15:20 – 15:40

F. Šimko (Bratislava, Slovakia) Evidence-based cardiovascular medicine: perspectives and disappointments

15:40 – 17:00

COFFEE BREAK & POSTER SESSION I.

17:00 – 19:00

SESSION 3. NOVEL TARGETS FOR CARDIOPROTECTION

Chairs: B. Podesser (Vienna, Austria) , J. Slezák (Bratislava, Slovakia)

17:00 – 17:20

A. Adameová (Bratislava, Slovakia) RIP3 mediates necroptosis and non-necroptotic inflammatory response: an interesting pharmacological tool for treatment of heart diseases

17:20 – 17:40

B. Podesser, A. Kiss, P. Pokreis, L. Szabo, C. Dostal (Vienna, Austria) Extracellular matrix remodeling under pressure overload

17:40 – 18:00

P. Bencsik , T. Szabados, É. Kenyeres, K. Gömöri, G. Dormán, A. Görbe, P. Ferdinandy (Szeged, Dunakeszi; Hungary) Development of novel matrix metalloproteinase-2 inhibitors for cardioprotection against ischemia/reperfusion injury: from chemical design to preclinical proof-of-concept studies

4